Puma triples on neratinib adjuvant breast cancer data
This article was originally published in Scrip
Puma Biotechnology's stock tripled in after-hours trading on 22 July after the company said it would seek regulatory approval based on Phase III results for its tyrosine kinase inhibitor neratinib in a Phase III clinical trial for the extended adjuvant treatment of breast cancer.
You may also be interested in...
Ponda Motsepe-Ditshego, who leads Amgen’s clinical trial diversity efforts, admits they are in early stages but noted progress internally and externally at better representing diverse patient groups.
VC funding slowed recently, but public company financings kept up a brisk pace with follow-on public offerings for Allakos and Alpine, private placements for Ventyx and Syros, and Albireo’s royalty deal. In restructuring updates, Biogen raised $592m in a real estate deal and Acerus is assessing options.
Private Company Edition: Acelyrin will use its latest funding for Phase III development of izokibep in inflammatory diseases. Also, ArsenalBio raised $220m to take its programmable cell therapies into the clinic and RayzeBio’s $160m series D round will fund clinical trials for its radiopharmaceuticals.